<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581330</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2020-0827</org_study_id>
    <nct_id>NCT04581330</nct_id>
  </id_info>
  <brief_title>The Effects of Fractional CO2 Laser on Poikiloderma of Civatte</brief_title>
  <official_title>The Effects of Fractional CO2 Laser on Poikiloderma of Civatte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of fractional CO2 laser treatment for&#xD;
      Poikiloderma of Civatte (POC).POC is a chronic vascular and pigmentary disorder typically&#xD;
      involving the lateral and inferior neck region, as well as the chest area. Clinically,&#xD;
      poikiloderma appears as a combination of telangiectasia, irregular pigmentation, and atrophic&#xD;
      changes.Little data exist regarding the use of fractional CO2 laser for management of POC.&#xD;
      This study hopes to fulfill this purpose. The primary outcome will be a blinded assessment by&#xD;
      dermatologists in the improvement in POC using the Physician's Global Aesthetic Improvement&#xD;
      Scale following therapy. The secondary outcomes include subject satisfaction post-treatment&#xD;
      and assessment of all procedure-related adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Change of Poikiloderma of Civatte (POC)</measure>
    <time_frame>12 weeks and 24 weeks post-treatment</time_frame>
    <description>Blinded dermatologists' assessment of POC change using the Physician Global Aesthetic Improvement Scale. Physician Global Aesthetic Improvement Scale ranges from 1 to 5, lower score indicating highest improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Change of Subject Satisfaction</measure>
    <time_frame>12 weeks and 24 weeks post-treatment</time_frame>
    <description>Subjects will assess satisfaction with change of POC using a 5-point satisfaction scale. Scale ranges from 1 to 5, lower score indicating lower satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subject with at least one adverse event</measure>
    <time_frame>Followed for 24 weeks post-laser treatment</time_frame>
    <description>Number of participants who experience adverse events &gt;=Grade 3, as defined by Common Terminology Criteria for Adverse Events by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Poikiloderma of Civatte</condition>
  <arm_group>
    <arm_group_label>DEKA SmartXide C02 laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One half of the subject's neck will be treated with ablative fractional CO2 laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEKA SmartXide C02 laser</intervention_name>
    <description>One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used</description>
    <arm_group_label>DEKA SmartXide C02 laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, English and non-English speakers, and subjects more than 18&#xD;
             years old&#xD;
&#xD;
          -  Clinical diagnosis of poikiloderma of Civatte affecting the neck and chest&#xD;
&#xD;
          -  Agree to not undergo any other procedures on the neck and chest area during the study&#xD;
&#xD;
          -  Agree to refrain from tanning for 6 months post-procedure&#xD;
&#xD;
          -  Willing and able to read, understand, and sign the consent form&#xD;
&#xD;
          -  Willing and able to adhere to the treatment and follow-up schedule as well as&#xD;
             post-treatment care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years old&#xD;
&#xD;
          -  Active skin infection, dermatitis, or a rash on the treatment area&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Patients on immunosuppressive medications&#xD;
&#xD;
          -  Any laser procedures or chemical peel procedures on the neck or chest area within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Patients with multiple comorbidities such as diabetes mellitus, cardiovascular&#xD;
             diseases, neurologic disorders, internal malignancies&#xD;
&#xD;
          -  Personal history or family history of forming keloids or hypertrophic scars, or&#xD;
             abnormal wound healing&#xD;
&#xD;
          -  Patients with known bleeding disorders or taking more than one anticoagulation&#xD;
             medications&#xD;
&#xD;
          -  Undergoing any surgery in the treatment area within the past 12 months&#xD;
&#xD;
          -  History of radiation to the head, neck, and chest area&#xD;
&#xD;
          -  Systemic use of isotretinoin within 6 months&#xD;
&#xD;
          -  Any use of gold therapy&#xD;
&#xD;
          -  Current smoker or history of smoking within 12 months of study&#xD;
&#xD;
          -  Any physical or mental condition in which the investigators deem unsafe for the&#xD;
             subject to participate in the study.&#xD;
&#xD;
          -  History of recurrent herpes simplex on the neck or chest.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather W Goff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Katoulis AC, Stavrianeas NG, Georgala S, Bozi E, Kalogeromitros D, Koumantaki E, Katsambas AD. Poikiloderma of Civatte: a clinical and epidemiological study. J Eur Acad Dermatol Venereol. 2005 Jul;19(4):444-8.</citation>
    <PMID>15987290</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Heather Woodworth Goff</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

